Recro Pharma, Inc. 4
4 · Recro Pharma, Inc. · Filed Aug 3, 2016
Insider Transaction Report
Form 4
Mack Randall
Senior VP, Development
Transactions
- Exercise/Conversion
Common Stock
2016-08-01+6,100→ 8,100 total - Tax Payment
Common Stock
2016-08-01$9.70/sh−2,546$24,696→ 5,554 total
Footnotes (1)
- [F1]On August 1, 2016, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 6,100 performance-based restricted stock units, which were converted into 6,100 shares of common stock on a one-for-one basis.